Omeros, a clinical-stage biopharmaceutical company focused on inflammation and disorders of the central nervous system, filed with the SEC for an IPO on Wednesday. Deutsche Bank is the lead manager on the deal. The company has applied to have their common stock listed on the NASDAQ under the ticker OMER. No terms were disclosed in the initial filing.
